KALA BIO, Inc. (KALA)
| Market Cap | 106.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.98M |
| Shares Out | 929.49M |
| EPS (ttm) | -3.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,572,128 |
| Open | 0.119 |
| Previous Close | 0.119 |
| Day's Range | 0.102 - 0.120 |
| 52-Week Range | 0.102 - 20.600 |
| Beta | -1.99 |
| Analysts | Buy |
| Price Target | 31.50 (+27,410.92%) |
| Earnings Date | Apr 15, 2026 |
About KALA
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for KALA stock is "Buy." The 12-month stock price target is $31.5, which is an increase of 27,410.92% from the latest price.
News
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, develop...
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Genera...
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO ...
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto,...
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA) Toronto, Ontari...
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to ...
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative to buil...
KALA BIO Transcript: AGM 2026
The meeting covered seven proposals, including director elections, executive compensation, auditor ratification, stock issuance, share increase, and a potential reverse split. All proposals passed by majority vote, and no questions were raised by stockholders.
KALA BIO Settles Approximately $10.6 million of Debt
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“...
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggreg...
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A novel stem cell secretome platform is advancing in late-stage trials for persistent corneal epithelial defects, aiming to address all underlying causes with a simple, effective eye drop. Top-line phase IIb data are expected soon, targeting a large unmet market.
KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Panelists highlighted advances in therapies for dry eye, corneal healing, neuropathic pain, and glaucoma, emphasizing novel mechanisms, strong early efficacy, and improved tolerability. Commercial strategies focus on access and combination products, while adoption barriers include reimbursement and regulatory hurdles.
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 mill...
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
KALA BIO Transcript: Status Update
KPI-012, a mesenchymal stem cell secretome therapy, targets all etiologies of persistent corneal epithelial defect, addressing a $3+ billion U.S. market with significant unmet need. Phase I-B data showed rapid, sustained healing and pain reduction, and the pivotal CHASE trial is underway with top-line results expected in Q3 2025.
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on p...
KALA BIO Transcript: Jefferies Global Healthcare Conference 2025
KPI-012, a mesenchymal stem cell secretome therapy, is in pivotal trials for persistent corneal epithelial defects, aiming for a broad indication and improved patient experience. Early clinical data show strong efficacy and safety, with top-line results expected in Q3.
KALA BIO to Present at Jefferies Global Healthcare Conference
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t...
KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference
Advancing secretome therapies for orphan eye diseases, the lead program targets PCED with broad potential and expects pivotal Phase IIb data by mid-2025. Strong financials support operations into 2026, with plans to expand indications if successful.
KALA BIO Announces Chief Executive Officer Transition
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
KALA BIO Announces $10,750,000 Private Placement
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference
A novel mesenchymal stem cell secretome therapy is advancing in phase IIb trials for persistent corneal epithelial defects, targeting a broad indication and significant unmet need. Early clinical data show strong efficacy and safety, with top-line results expected in Q2 2025.